Ademi LLP is investigating possible securities fraud claims against Ardelyx (Nasdaq: ARDX). The investigation results from inaccurate statements Ardelyx may have made regarding its business operations and prospects.
The investigation focuses on whether Ardelyx properly disclosed the size of the treatment effect and its clinical relevance with respect to Ardelyx’s clinical trial for tenapanor, used in the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.